DUBLIN--(BUSINESS WIRE)--The "2018 Liver Failure Drug Development- Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.
Hepatic Insufficiency is a rare disease that can either present slow or rapid worsening of liver functioning. Young population is the most affected age group. The disease presents high mortality rates. Hepatitis infection, medication issues, alcohol are the primary reasons of the disease.
Over 30 companies and universities are focusing on developing treatment options for Liver Failure (Hepatic Insufficiency).
To assist investigators and funding and regulatory organizations, the publisher has come up with a comprehensive report on Liver Failure (Hepatic Insufficiency) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Liver Failure (Hepatic Insufficiency) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Liver Failure (Hepatic Insufficiency) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Key Topics Covered:
1 Tables & Figures
2 Liver Failure Pipeline Analysis
2.1 Disease and Pipeline Overview
2.2 Liver Failure Pipeline Snapshot
2.3 Liver Failure Pipeline by Phase
2.4 Liver Failure Pipeline by Company
2.5 Liver Failure Pipeline by Mechanism of Action
3 Liver Failure - Company Wise Pipeline Analysis
- HepaRegeniX GmbH
- Martin Pharmaceuticals
- Mina Therapeutics
- Novartis AG
- PledPharma AB
- Promethera Biosciences
- Proterris Inc
- Steminent Biotherapeutics Inc
- Therapure Biopharma
- Unicyte AG
- Versantis AG
- Vital Therapies Inc
- Xenexus Pharmaceuticals
4 Liver Failure R&D Pipeline Snapshots
Drug wise Pipeline Details
Therapeutic Candidate Name
Co-Developer/ License Partner
Orphan Drug Designation
Mechanism of Action
Ongoing Clinical Trial Details
5 Recent Developments in Liver Failure Pipeline
For more information about this report visit https://www.researchandmarkets.com/research/g4lsr4/2018_liver?w=4